Page 2 - Per Persson News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Acarix AB: Positive, long term prognostic data from the Dan-NICAD I study published in European Heart Journal- Digital Health Positive, long term prognostic data from the Dan-NICAD I study published in European Heart Journal- Digital Health Acarix AB (publ) today announced the publication of the Prognostic study, a study with long term follow up on patients from the Dan-NICAD 1 publication. The long term Prognostic data from the Dan-NICAD 1 trial was first presented at the ESC Congress in September 2019 by Simon Winther, MD, PhD from Aarhus University Hospital, Denmark. The Dan-NICAD 1 trial...

Acarix AB: A strong ending of an eventful year A strong ending of an eventful year The fourth quarter contributed strongly to our overall performance in 2020, with the market approval for CADScor from the US Food and Drug Administration (FDA) as the outstanding achievement. Extract from CEO Per Persson's message to the End Year Report. Fourth quarter 2020 compared with same period 2019 During the fourth quarter, 22 CADScorSystem (10, of which 4 to clinical trials) and 1,420 (1,500, of which 840 to clinical trials) disposable patches were sold to end-users and distributors. Revenue amounted to...

Positive preliminary data from Acarix’s exploratory heart failure study SEISMO Acarix AB (publ) today announced positive preliminary data from the exploratory SEISMO study, using its modified CADScor ®System on a potential heart failure application. The SEISMO trial was initiated in June 2018 to evaluate the possibility of developing an algorithm that can differentiate patients referred with suspicion of heart failure. The study, with in total 199 patients at two sites in Denmark, included the last patient in 2020. "Completing the inclusion to the exploratory heart failure study was a grea...

Acarix AB: Positive preliminary data from Acarix's exploratory heart failure study SEISMO Positive preliminary data from Acarix's exploratory heart failure study SEISMO Acarix AB (publ) today announced positive preliminary data from the exploratory SEISMO study, using its modified CADScor System on a potential heart failure application. The SEISMO trial was initiated in June 2018 to evaluate the possibility of developing an algorithm that can differentiate patients referred with suspicion of heart failure. The study, with in total 199 patients at two sites in Denmark, included the last patien...